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Abstract
Introduction: Breast cancer remains the second leading cause of cancer-related deaths for women in the United
States. Metastasis is regulated not only by intrinsic genetic changes in malignant cells, but also by the
microenvironment, especially those associated with chronic inflammation. We recently reported that mice with
autoimmune arthritis have significantly increased incidence of bone and lung metastasis and decreased survival
associated with breast cancer. In this study, we evaluated the mechanism underlying the increased metastasis.
Methods: We used two mouse models; one that develops spontaneous autoimmune arthritis (SKG mice) injected with
metastatic breast cancer cells (4T1), and another that develops spontaneous breast cancer (MMTV-PyV MT mice)
injected with type II collagen to induce autoimmune arthritis. Mast cell levels and metastasis were monitored.
Results: First, we confirmed that breast tumor-bearing arthritic mice have a significantly higher incidence of bone
and lung metastasis than do their nonarthritic counterparts. Next, we showed increased recruitment of mast cells
within the primary tumor of arthritic mice, which facilitates metastasis. Next, we report that arthritic mice without
any tumors have higher numbers of mast cells in the bones and lungs, which may be the underlying cause for the
enhanced lung and bone metastases observed in the arthritic mice. Next, we showed that once the tumor cells
populate the metastatic niches (bones and lungs), they further increase the mast cell population within the niche
and assist in enhancing metastasis. This may primarily be due to the interaction of c-Kit receptor present on mast
cells and stem cell factor (SCF, the ligand for ckit) expressed on tumor cells. Finally, we showed that targeting the
SCF/cKit interaction with an anti-ckit antibody reduces the differentiation of mast cells and consequently reduces
metastasis.
Conclusion: This is the first report to show that mast cells may play a critical role in remodeling not only the
tumor microenvironment but also the metastatic niche to facilitate efficient metastasis through SCF/cKit interaction
in breast cancer with arthritis.
Introduction
In 2012, an estimated 229,060 new cases of breast cancer
(BC) are expected to be diagnosed in women, and about
39,920 women are expected to die of the disease because
of metastasis [1]. The most common site of metastasis is
the bone, and bone-disseminated BC is incurable. Studies
in the past 10 years have begun to elucidate the role of
cytokines/chemokines and bone remodeling during BC-
associated bone metastasis [2-5]. Several studies demon-
strated that sites of chronic inflammation are associated
with the establishment and growth of tumor cells [2]. One
such common inflammatory condition in humans is auto-
immune arthritis (AA), which causes inflammation and
deformity of the joints, as well as increased cellular infiltra-
tion and inflammation of the lungs [6]. Although AA and
BC are different diseases, some of the underlying molecu-
lar processes that characterize AA also affect cancer pro-
gression and metastasis. The bones and lungs not only are
the most common sites of chronic inflammation linked to
AA, but also are frequent sites of BC metastasis. In addi-
tion, epidemiologic studies indicate that BC patients with
rheumatoid arthritis (RA) have poor prognoses and higher
mortality in comparison with BC patients without RA [7].
Thus, an understanding of the molecular mechanisms and
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factors that facilitate BC-associated metastasis in arthritic
conditions is highly significant.
We reported that mice with AA have a significantly
increased incidence of bone and lung metastasis and
decreased survival associated with BC [8,9]. We further
demonstrated that critical proinflammatory factors (inter-
leukin-17 (IL-17), IL-6, matrix metallopeptidase-9 (MMP-
9), cyclooxygenase-2 (COX-2), vascular endothelial growth
factor (VEGF), and tumor necrosis factor-alpha (TNF-a))
triggered by AA serve as chemoattractants for recruitment,
retention, and proliferation of BC cells in the bones and
lungs [8,9]. Interestingly, these mentioned proinflamma-
tory factors are produced by mast cells (MCs), which can
be activated by tumor-derived SCF [10]. SCF is a cytokine/
ligand that binds to the c-Kit receptor (CD117) on MCs.
MCs are highlighted as a major regulator of inflammation
[11,12]. It is also reported that tumor-infiltrating MCs
remodel the tumor microenvironment and promote
tumor growth [10].
Thus, we hypothesized that the enhanced BC-asso-
ciated metastasis in the arthritic mice may be due to the
activation of MCs via the SCF/c-Kit interaction and that
disrupting this interaction may reduce metastasis. We
have used two relevant transgenic models that mimic
the human disease: one that develops spontaneous AA
(SKG mice) bearing orthotopic 4T1 tumors in the mam-
mary fat pad and another that develops spontaneous
mammary gland tumors (PyV MT mice) induced to
develop AA.
The SKG mice carry a mutation of the gene encoding
an SH2 domain of ZAP-70, a key signal-transduction
molecule in T cells, and spontaneously develop T cell-
mediated chronic AA [13]. The mutation impairs positive
and negative selection of T cells in the thymus, leading to
thymic production of arthritogenic autoimmune CD4+
T cells. The mice succumb to symmetrical joint swelling,
beginning in the small joints of the digits and progressing
to the larger joints. This is accompanied by severe syno-
vitis with formation of pannus that invades and erodes
the adjacent cartilage and subchondral bone. Genetic
deficiency of IL-6, IL-1, or TNF-a inhibits development
of AA in SKG mice [14], similar to the effects of anticyto-
kine therapy in human arthritis [15]. These mice, when
injected with the 4T1 tumor cells in the mammary fat
pad, develop metastatic BC. The clinical and immuno-
pathologic characteristics of AA in these mice make the
strain a suitable model for testing our hypothesis.
The PyV MT mice are an established model of meta-
static mammary gland tumors in a C57BL/6 background
[16,17]. These mice carry the polyoma middle-T antigen
driven by the MMTV promoter. The mice sponta-
neously develop mammary gland hyperplasia at puberty
and progress to develop carcinoma in situ and invasive
adenocarcinoma by 24 weeks of age. When injected
with type II collagen (CII), the PyV MT mice develop
typical signs of RA. The ensuing pathogenesis includes
synovial hyperplasia, mononuclear cell infiltration, and
cartilage degradation [18,19]. This model is clinically
relevant, as tumors are phenotypically similar to the
metastatic human breast tumors [16,17].
We first report the levels of MCs in the primary
tumors and metastatic niches (bone and lung). Next, we
demonstrate the significance of the SCF/cKit-receptor
signaling in inducing metastasis. Finally, we report that
interrupting the SCF/cKit receptor substantially reduces
BC-associated metastasis to the bone and lung.
Materials and methods
Mice
SKG mice were established from a closed breeding col-
ony of Balb/C mice [20]. At about 3 months old, mice
were injected with 1 × 105 4T1 cells (in 100 μl of PBS)
in the mammary fat pad. Balb/C mice were used as the
nonarthritic controls. After 35 days of tumor challenge,
all mice were killed, and analysis was conducted.
PyV MT oncogenic mice were originally a gift from
Dr. W. J. Muller (McGill University, Toronto, Ontario,
Canada) [17]. The PyV MT mice were bred to be con-
genic on the C57Bl/6 background and were used in sev-
eral of our prior publications [9,21-24]. Genotyping of
these mice was conducted as described previously [21].
All mice were bred and maintained in specific patho-
gen-free conditions in the UNCC Animal Facility. All
experimental procedures were conducted according to
Institutional Animal Care and Use Committee guidelines.
All protocols were approved by the UNCC Internal
Animal Care Review Committee (IACUC ID: 08-036.0
and 11-015.0).
Cell lines
The 4T1 cells were purchased from The American Type
Cell Culture Collection (Manassas, VA, USA). This
highly metastatic BC cell line is derived from a sponta-
neously arising Balb/C mammary tumor. Cells were
maintained in complete RPMI [8]. 4T1 tumors resemble
human late-stage metastatic BC [25-27].
The PyV MT cell lines were generated from PyV MT
tumors and cultured as previously described in complete
DMEM [9].
Induction of arthritis
The PyV MT mice were injected with 50 μl of 2-mg/ml
CII (MD Biosciences, St. Paul, MN, USA) in CFA (Difco
Laboratories, Detroit, MI, USA) intradermally about
1.5 cm distal from the base of the tail at 12 weeks of age.
Fifty-sixty percent of mice developed arthritis within 15
to 30 days after collagen injection [28]. All mice were
killed at 22 weeks, and analysis was conducted.
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Flow cytometry
BMMCs were stained with FITC rat anti-mouse CD117
antibody (BD Pharmingen, San Diego, CA, USA). Acqui-
sition was performed on a FACS Fortessa Cytometer,
and analysis was performed by using the Flow Jo
program.
Western blot and antibodies
We performed BCA assay to load equal quantities of
tumor lysates onto sodium dodecylsulfate-polymerase
chain reaction (SDS-PAGE) gels. SCF and b-actin anti-
bodies were used at 1:200 dilution (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and were used according
to manufacturer’s recommendations.
The densitometric analyses of immunoblots as shown
in Additional file 1 were performed by using NIH Ima-
ging program. Results are presented as mean values of
arbitrary densitometric units corrected for background
intensity and normalized to the expression of b-actin.
Histology
Lungs, bones, and tumor sections were processed as
previously described [8,9]. Paraffin-embedded blocks
were prepared, and 4-μm-thick sections were cut for
hematoxylin/eosin (H&E) and pancytokeratin staining.
The pancytokeratin antibody was purchased from Santa
Cruz and used at 1:50 dilution by following the same
protocol as described in our previous publications [8,9].
To establish the expression of MCs on the tumors,
lungs, and bones, anti-mast cell tryptase antibody
(ab134932) was purchased from Abcam, Cambridge,
MA, USA.
To establish further the expression of MCs, toluidine
blue purchased from Fluka Analytical (Exeter, Devon,
UK) distributed by Sigma-Aldrich (Sigma Aldrich, St.
Louis, MO, USA) was used as directed by the manufac-
turer. All images were taken by using Olympus DP71
light microscopy.
Immunofluorescence
Cells were plated on chamber slides and grown to 75%
confluency followed by immunofluorescence (IF) stain-
ing with SCF rabbit antibody at 1:200 dilution and Alex-
afluor 594 donkey anti-rabbit (Invitrogen) secondary at
1:1,000. Staining was performed as previously described
[29]. Slides were examined under Olympus FV1000
fluorescence microscopy, and pictures were taken at
400× magnification.
Generation of bone marrow-derived mast cells
BM cells were harvested from femurs of mice, and 2 ×
106 cells were cultured, as previously described [10].
The cells were cultured in the presence of 10 ng/ml
IL-3 and 50 ng of recombinant murine SCF (PeproTech,
Rocky Hill, NJ, USA), and the nonadherent cells were
passaged every 3 days. Four weeks later, the cells were
used as MCs for experiments [10,30]. The MCs were
identified and counted in three different ways: (a) light
microscopy: we counted the MCs with a hemocytometer
and used trypan blue to detect any dead cells [30]; (b)
flow cytometry: BMMCs were stained with FITC rat
anti-mouse CD117 antibody, and the percentage of MCs
was analyzed with flow cytometry. CD117 is the cKit
receptor present on mast cells; and (c) toluidine staining
[30]. We counted five fields of toluidine-positive
BMMCs generated from BM derived from each mouse.
Isolation of viable circulating BC cells
Blood samples (0.5 to 1.0 ml) were obtained by cardiac
puncture from individual tumor-bearing animals by
using heparin as the anticoagulant and processed as
described previously [29,31].
Cells were cultured in complete DMEM for 21 days.
Migration assays
SCF expressing 4T1 and PyV MT cells were plated over
transwell inserts in the upper chamber (BD Biosciences,
San Diego, CA, USA) and permitted to migrate toward
MCs in the lower chamber for 15 hours. Percentage
migration was determined as described earlier [29]. We
added neutralizing SCF antibody (R&D Systems, Minnea-
polis, MN, USA) to tumor cells or anti-cKit antibody
(eBioscience, San Diego, CA, USA) to the MCs as inde-
pendent groups for 12 hours and analyzed the migration
of BC cells toward MCs.
X-ray imaging
The Pix array 100 x-ray machine (Bi Optic Inc, Santa
Clara, CA, USA) was used for bone imaging, as described
[32].
Treatment schema
When the tumors were about 5 mm in length (after
about 6 days of 4T1 injections), mice were injected (IP)
with neutralizing rat anti-mouse cKit-receptor antibody
(50 μg) (eBioscience) or 20 μg goat anti-mouse-SCF
antibody (R&D Systems, Minneapolis, MN, USA) once a
week for 4 weeks. The mice were euthanized 24 hours
after the last injections at about 35 days after tumor
challenge. For treatment experiments, 4T1 cells trans-
fected with green fluorescent protein (4T1-GFP) were
injected.
Statistical analysis
Data were analyzed by using GraphPad software. Results
are expressed as mean ± SEM and are representative of
three or more separate experiments. Comparison of
groups was done by using one-way or two-way ANOVA
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followed by the Bonferroni posttest for multiple compari-
sons (*P < 0.05, **P < 0.01, ***P < 0.001). The Student t
test was used for comparing the level of significance
between two experimental groups.
Results
Significant increase in primary tumor burden as well as
lung and bone metastasis in the arthritic versus
nonarthritic mice with breast cancer
We first demonstrated that the 4T1 tumor burden is sig-
nificantly higher in the arthritic SKG versus the nonar-
thritic Balb/C mice (Figure 1A). Second, we substantiated
this finding in the PyV MT mice with higher tumor bur-
den in the arthritic PyV MT versus the nonarthritic PyV
MT mice (Figure 1B). Third, metastases to the lungs and
bones were compared. We report that nine of 10 SKG
mice showed lung metastasis, whereas only four of 10
Balb/C mice showed metastasis (Figure 1C). Similarly,
seven of 10 arthritic PyV MT mice showed lung metasta-
sis, whereas only three of 10 nonarthritic Py VMT mice
showed the same (Figure 1C). Similar trends were
observed with bone metastasis, with eight of 10 SKG mice
developing bone metastasis, whereas only three of 10
Balb/C developing the same (Figure 1D). Likewise, five of
10 arthritic PyV MT mice developed bone metastasis,
whereas none of the nonarthritic PyV MT mice developed
bone metastasis (Figure 1D).
Circulating tumor cells (CTCs) are being aggressively
explored as a prognostic tool and a measure of metastasis
and response to therapy [29,31]. One way to evaluate
CTCs in mice is to culture the blood and detect colonies
of tumor cells. We detected higher levels of CTCs (that
formed colonies within 3 weeks of culture) in the blood of
the tumor-bearing arthritic mice compared with the blood
from the tumor-bearing nonarthritic mice (Figure 1E).
The data corroborate our previous studies [8,9] and
further establish that the proinflammatory microenviron-
ment created in bones and lungs by AA is highly condu-
cive for BC cells to form metastases.
Mast cell population in the tumor microenvironment and
metastatic niche
We first assessed the expression of MCs in the tumor
and metastatic niches (bone and lung). Tryptase is the
most abundant secretory granule-derived serine con-
tained in MCs that has been used as a marker for MC
activation. In addition, tryptase has been shown to be a
sensitive and specific marker for the localization of MCs
in tissues [33-35]. By doing MC tryptase staining by
IHC, we detected significantly higher numbers of MCs
in the tumors of arthritic versus nonarthritic mice with
BC (Figure 2A). We detected infiltration of MCs in the
tumors of SKG versus Balb/C mice with BC (Figure 2B)
and in the PyV MT mice induced with arthritis versus
PyV MT mice with no arthritis (Figure 2C). We further
identified significantly higher levels of MCs in the sites
of metastasis: lungs (Figure 3) and bones (Figure 4) of
arthritic versus nonarthritic mice in both (SKG and PyV
MT) models. Thus, data suggest that an increase in MC
migration and activation occurs within the tumor as
well as in the metastatic niches, as indicated by the
increased MC expression.
However, to confirm further the in vivo infiltration of
MCs, toluidine staining was also conducted on tissue sec-
tions. MCs contain granules (metachromatic) composed
of heparin and histamine. Toluidine blue stains MC blue-
purple (metachromatic staining) and the background
blue (orthochromatic staining). Clearly, in both the
arthritic PyV MT and SKG mice, we observe a signifi-
cantly increased infiltration of MCs within the tumor
(Figure 5A, B), lung (Figure 5C, D), and bone (Figure 5E,
F). Shown in Figures 2 through 5 are representative MC
staining in the tissues from one mouse per experimental
group. Also shown in Figure 5B is a magnified image of
MC infiltration in the 4T1 tumor section of an arthritic
SKG mouse. To quantitate the results from Figures 2
through 5, MCs were counted under the microscope (six
mice per experimental group and 10 fields per section
per organ), and the mean numbers reflected in the graph.
Most important, we noted that in the non-tumor-
bearing arthritic mice (SKG and CII-injected C57BL/6
mice), the number of MCs was increased compared
with nonarthritic tumor-bearing Balb/C or PyV MT
mice (Figures 3 through 5), indicating that the arthritic
milieu by itself can increase the MC population in the
bones and lungs, creating a conducive niche that attracts
the SCF-expressing tumor cells. The MC expression in
the lungs and bones of nonarthritic Balb/C and C57BL/
6 mice with no tumor was found to be negligible (data
not shown). We therefore believe that once tumor cells
populate the bone and lungs, the tumor-derived SCF
binds to the c-Kit receptor on MCs and helps in the dif-
ferentiation, maturation, and survival of MCs, remodel-
ing the microenvironment and further increasing the
population of MCs [10] and Figures 2 through 5. Thus,
the higher tumor burden and metastases seen in the
arthritic mice (Figure 1) may be due to the increase in
MC infiltration in the tumors and metastatic niches.
SCF expression on the tumors
To confirm that MC activation and proliferation in the
tumors and sites of metastasis may be mediated by
tumor-derived SCF, we assessed the expression of SCF
on 4T1 and PyV MT tumors in vivo by Western blotting.
We observed that SCF was highly expressed by the 4T1
and PyV MT tumors in vivo (Figure 6A). No difference
was found in SCF protein expression levels between
tumors derived from arthritic versus nonarthritic mice,
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Figure 1 Higher tumor burden coupled with higher metastasis in arthritic versus nonarthritic breast cancer-bearing mice. (A, B)
Significant increase in tumor burden in SKG versus Balb/C (*P < 0.05) and arthritic PyV MT versus PyV MT (*P < 0.05) mice. (C, D) Percentage of
lung and bone metastasis, respectively. (E) Light-microscopic images of circulating tumor cells cultured from peripheral blood of arthritic versus
nonarthritic tumor-bearing mice. (A through E, 10 mice).
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Figure 2 Expression of mast cells (MCs) tryptase staining on tumors. (A) Significant increase in MCs tryptase count in the tumors of arthritic
SKG mice challenged with 4T1 cells versus nonarthritic Balb/C mice injected with 4T1 cells (**P < 0.01) and in arthritic PyV MT mice induced
with CII versus nonarthritic PyV MT mice (**P < 0.01). Representative images of tryptase staining in (B, C): tumors taken at 400× magnification
(six mice per experimental group and 10 fields per section). Brown staining represents MCs tryptase expression.
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Figure 3 Expression of mast cells (MCs) tryptase staining on lungs. (A) Significant increase in MCs tryptase count in the lungs of arthritic
SKG mice challenged with 4T1 cells versus nonarthritic Balb/C mice injected with 4T1 cells (***P < 0.001) and in arthritic PyV MT mice induced
with CII versus nonarthritic PyV MT mice (***P < 0.001). Significant increase in MCs tryptase also is observed in the lungs of arthritic SKG mice
with no tumor versus Balb/C mice with breast cancer (BC; *P < 0.05). Similarly, we see the same trend in arthritic C57BL/6 mice induced with CII
versus spontaneous BC model of PyV MT mice with no arthritis (*P < 0.05). Representative images of tryptase staining in (B, C) lungs taken at
600× magnification (six mice per experimental group and 10 fields per section). Brown staining represents MCs tryptase expression.
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Figure 4 Expression of mast cells (MCs) tryptase staining on bones. (A) Significant increase in MCs tryptase count in the bones of arthritic
SKG mice challenged with 4T1 cells versus nonarthritic Balb/C mice injected with 4T1 cells (***P < 0.001) and in arthritic PyV MT mice induced
with CII versus nonarthritic PyV MT mice (***P < 0.001). Significant increase in MCs tryptase also is observed in the bones of arthritic SKG mice
with no tumor versus Balb/C mice with BC (*P < 0.05). Similarly, although not significant, we see the same trend in arthritic C57BL/6 mice
induced with CII versus a spontaneous BC model of PyV MT mice with no arthritis. Representative images of tryptase staining in (B, C) bones
taken at 400× magnification (six mice per experimental group and 10 fields per section). Brown staining represents MCs tryptase expression.
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Figure 5 Toluidine staining to confirm mast cell (MC) expression. Significant increase in MCs toluidine count in arthritic mice with BC (SKG
+4T1 and PyV MT+CII) versus nonarthritic (Balb/C+4T1 and PyV MT) BC models in (A) tumors (**P < 0.01), (C) lungs (***P < 0.001), and (E)
bones (***P < 0.001; **P < 0.01). Significant increase in MCs toluidine staining was also observed in arthritic control (SKG and C57BL/6+CII) mice
with no tumor as compared with nonarthritic (Balb/C mice with BC and spontaneous BC PyV MT mice) in (C) lungs (*P < 0.05) and (E) bones (*P
< 0.05). We observed the same trend of MC expression with toluidine staining in tumors, lungs, and bones of arthritic versus nonarthritic BC
models as in MCs tryptase staining (Figures 2 through 4). Representative images of toluidine staining in (B) tumors (200×), (D) lungs (400×), and
(F) bones (400×) (six mice per experimental group and 10 fields per section per organ). Purple-blue staining represents MCs toluidine expression.
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indicating that the arthritic milieu does not influence
SCF levels. SCF expression was also confirmed on 4T1
and PyV MT tumor cell lines in vitro by IF (Figure 6B).
Increased differentiation of MCs from BM-derived
hematopoietic precursors in arthritic versus nonarthritic
mice with BC
Because we observed increased MCs in the arthritic mice
even in the absence of a tumor, we determined whether
the differentiation of MCs from the bone marrow-derived
precursors was affected by the arthritic milieu. We cul-
tured 2 × 106 BM cells in the presence of IL-3 and SCF
for 30 days to induce the precursor cells to differentiate
into MCs. BM cells differentiate into MCs under selec-
tion with recombinant IL-3 and SCF [30]. We observed
significant increase in the bone marrow-derived mast
cells (BMMCs) in non-tumor-bearing arthritic SKG and
C57BL/6+CII mice versus Balb/C with tumor or PyV MT
mice (Figure 7A and 7C; Tables 1 and 2). Balb/C or
C57BL/6 had no detectable levels of mast cells (Table 1
and 2). Numbers of MCs are represented in Figure 7A
and 7C, respectively. Light-microscopic images of differ-
entiated MCs from representative groups are shown in
Figure 7B and 7D, respectively. Significant increase in
MC differentiation was observed in tumor-bearing SKG
and arthritic PyV MT mice as compared with tumor-
bearing nonarthritic Balb/C mice and nonarthritic PyV
MT mice (Figure 7A through D). Because differentiated
mast cells should express the c-Kit receptor, we stained
the cells with a c-Kit antibody (CD117) and analyzed with
flow cytometry. A representative histogram is shown in
Figure 7E and 7F. To confirm that the differentiated cells
were indeed MCs, toluidine staining was conducted, and
representative staining is shown in Figure 7G. Data sug-
gest that the BM-derived precursor cells that are predes-
tined to differentiate into MCs are significantly higher in
the arthritic BM milieu before tumors are formed and that









Balb/C    SKG
1    2    3   1    2     3
PyV MT   PyV MT+CII
45
 K
D1    2    3   1    2     3
SC
F
4T1 cells PyV MT cells
B
SCF expression on tumors from arthritic versus 
non-arthritic BC models
SCF expression on in vitro breast cancer cell lines
Figure 6 The expression of stem cell factor (SCF) on the 4T1 and PyV MT cells in vivo and in vitro. (A, B) Western blotting showing the
presence of SCF on the tumors derived from experimental mice, as indicated in the figure (three tumors). (C, D) Immunofluorescence
confirming the presence of SCF on the 4T1 and PyV MT cells in vitro.
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Figure 7 Increased migration and differentiation. (A through G) Increased differentiation of mast cells (MCs) from bone marrow (BM)-
derived hematopoeitic precursors in arthritic versus nonarthritic mice with breast cancer (BC). Significant increase in MC count in (A) ± tumor-
bearing SKG (*P < 0.05; **P < 001) and (C) arthritic C57BL/6 and PyV MT (*P < 0.05; **P < 001) mice (10 mice). (B, D) Representative images of
MCs at 400× magnification. (E, F) Flow-cytometric analysis of percentage of cells expressing cKit receptor (CD117) on MCs. (G) Representative
image of toluidine staining for MCs (1,000× magnification). (H, I) Increased migration of tumor cells toward MCs derived from arthritic tumor-
bearing mice. Significant increase in migration of 4T1 and PyV MT cells toward the MCs from tumor-bearing arthritic mice (BMMCs) (**P < 001
and *P < 0.05). (H, I) Treatment of tumor cells with anti-SCF antibody or MCs with anti-c-Kit antibody decreased the migration of tumor cells
toward mast cells. Pretreatment of 4T1 and PyV MT cells with anti-SCF antibody or adding anti-c-Kit antibody to the MCs in the lower chamber
significantly decreased the migration of the tumor cells toward the MCs (*P < 0.05; **P < 0.01; ***P < 0.001).
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and 2). It can therefore be speculated that AA probably
affects hematopoiesis and induces the production of MCs,
thus creating a microenvironment appropriate for tumor
cells to home and form metastases.
Migration of tumor cells toward mast cells is decreased
when tumor cells are treated with anti-SCF or when mast
cells are treated with anti-c-Kit antibodies
To determine that the chemotactic migration of tumor
cells into metastatic sites is indeed mediated by MCs, and
SCF on tumors and c-Kit on mast cells are necessary for
this, we conducted an in vitro migration assay. SCF
expressing 4T1 and PyV MT cells (as shown in Figure 6B)
were placed in the upper chamber, and BMMCs that
express c-Kit (Figure 7E, F) of arthritic and nonarthritic
mice in the lower chamber. We found significant increase
in the migration of 4T1 and PyV MT cells toward the
MCs that were derived from 4T1-bearing arthritic SKG or
PyV MT mice (Figure 7H and 7I, respectively). We further
showed that pretreatment of 4T1 and PyV MT cells with
anti-SCF antibody or adding anti-cKit antibody to the
BMMCs in the lower chamber significantly decreased the
migration of the tumor cells toward the MCs (Figure 7H
and 7I). The data suggest that the SCF/c-Kit signaling may
be one of the drivers of BC-associated bone and lung
metastasis.
Blocking the SCF-cKit interaction significantly decreases
the metastasis of 4T1 tumors toward the lungs and
bones of SKG mice
A key finding from this study indicates that the SCF/c-Kit
signaling was necessary for the tumor cells to migrate
toward the MCs in an in vitro migration assay. This set the
stage for examining the effects of blocking this signaling in
vivo. When mice were treated with therapy to target the c-
Kit receptor or SCF, a significant decrease in tumor burden
was noted in the mice treated with anti-cKit antibody but
not with anti-SCF antibody (Figure 8A). However, metasta-
sis to the lungs (Figure 8B through E) and bone (Figure 8F
through I) was significantly reduced in both treatment
groups. We observed about threefold and about twofold
decrease in lung metastasis in mice treated with anti-cKit
and anti-SCF, respectively (Figure 8B). Figure 8C shows
representative images of GFP-positive 4T1 cells in the
lungs of SKG mice injected with 4T1 cells with no treat-
ment versus the treated groups. Figure 8D shows the meta-
static lesions in the lungs and the pancytokeratin staining,
Table 1 Number of bone marrow mast cells generated
from bone marrow of Balb/C versus SKG mice induced












Balb/C 1 0 1 0 1 0 0.4 0.55
Balb/C 1 1 0 0 0 0 0.2 0.45
Balb/C 1 0 0 1 0 1 0.4 0.55
SKG 1 6 4 6 5 7 5.6 1.14
SKG 2 7 5 4 6 8 6 1.58
SKG 3 5 8 7 9 4 6.6 2.07
Balb/C + 4T1
1
0 3 1 0 2 1.2 1.30
Balb/C + 4T1
2
0 0 3 1 0 0.8 1.30
Balb/C + 4T1
3
0 2 0 0 0 0.4 0.89
Balb/C + 4T1
4
1 2 1 0 1 1 0.71
Balb/C + 4T1
5
3 0 0 2 0 1 1.41
Balb/C + 4T1
6
1 0 1 1 0 0.6 0.55
SKG + 4T1 1 18 19 15 14 14 16 2.35
SKG + 4T1 2 17 15 12 17 17 15.6 2.19
SKG + 4T1 3 13 14 15 13 11 13.2 1.48
SKG + 4T1 4 11 13 11 16 15 13.2 2.28
SKG + 4T1 5 18 16 15 18 19 17.2 1.64
SKG + 4T1 6 20 17 21 15 17 18 2.45
Table 2 Number of bone marrow mast cells generated
from bone marrow of PyV MT mice with and without












C57BL/6 1 1 1 0 0 1 0.6 0.55
C57BL/6 2 0 1 0 0 0 0.2 0.45
C57BL/6 3 0 1 1 0 0 0.4 0.55
C57BL/6+CII
1
3 5 4 6 5 4.6 1.14
C57BL/6+CII
2
4 6 5 3 4 4.4 1.14
C57BL/6+CII
3
3 5 5 6 4 4.6 1.14
PyV MT 1 2 3 4 5 5 3.8 1.30
PyV MT 2 4 2 3 4 2 3 1.00
PyV MT 3 3 4 2 3 2 2.8 0.84
PyV MT 4 1 3 2 1 1 1.6 0.89
PyV MT 5 3 2 1 1 3 2 1.00
PyV MT 6 5 1 1 2 0 1.8 1.92
PyV MT+CII
1
13 12 11 12 11 11.8 0.84
PyV MT+CII
2
11 12 11 9 10 10.6 1.14
PyV MT+CII
3
8 14 11 9 7 9.8 2.77
PyV MT+CII
4
10 7 9 13 11 10 2.24
PyV MT+CII
5
9 7 12 11 15 10.8 3.03
PyV MT+CII
6
11 16 13 8 12 12 2.92
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GFP positive cells on lungs*
Figure 8 Diminution of lung and bone metastasis by interrupting the SCF/cKit signaling. (A) Significant decrease in tumor burden in the
mice treated with anti-cKit (*P < 0.05). (B) Percentage incidence of lung metastasis by blocking the SCF/cKit signaling. (C) Representative images
of 4T1-GFP cells in lungs of arthritic mice with no treatment. (D, E) Representative images of (D) H&E (200×) and (E) pancytokeratin (400×)
staining of lungs to confirm micrometastasis. (F) Percentage incidence of bone metastasis by blocking the SCF/cKit signaling. (G, H)
Representative images of pancytokeratin staining of (G) BM (200×) and (H) bone tissue (200×) to confirm metastasis. (I) Representative r-ray
images of metastatic bone lesions in arthritic model with no treatment. (A through I, 10 mice.) Brown staining represents pancytokeratin
positivity.
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confirming that the metastatic patches seen are epithelial
tumor cells (Figure 8E). Similarly, we observed about three-
fold and about twofold decrease in metastatic bone lesions
in mice treated with anti-cKit and anti-SCF, respectively
(Figure 8F). Pancytokeratin staining in the BM and bone
tissues (Figure 8G, H) and representative radiographic x-
ray bone images (Figure 8I) confirmed the presence of
epithelial tumor cells in the bones of these mice.
Significant decrease in differentiation of mast
cells from bone marrow precursors from the mice
treated with anti-cKit and anti-SCF therapy
To determine the effect of the therapy on MC differen-
tiation, we plated 2 × 106 cells from each treatment
group of mice. After about 30 days of culture with IL-3
and SCF, we observed a significant decrease in MC
population from the BM of mice treated with anti-cKit
and anti-SCF (Figure 9A through D), indicating that the
BM cells destined to differentiate to MCs are affected by
this therapy.
Next, we performed a migration assay by keeping the
4T1 cells in the upper chamber and MCs derived from
the mice with and without treatment in the lower cham-
ber. We saw a significant decrease in migration of 4T1
cells toward the MCs derived from the mice treated
with anti-cKit and anti-SCF (Figure 9E). This finding
illustrates that this therapeutic intervention not only
reduces the differentiation of MCs from BM precursors
but also affects migration of the tumor cells toward
those MCs. In all instances, treatment with anti-c-Kit
was significantly better than that with anti-SCF. The
reason for this is unknown, but one can speculate that
the anti-c-Kit antibody may have a superior neutralizing
effect.
Interrupting the SCF/c-Kit signaling significantly reduces
the numbers of mast cells infiltrating the tumor sites
Finally, to determine the levels of mast cells in the trea-
ted mice, we assessed the number of mast cells in the
tumor, bone, and lung of treated mice. We observed a
significant decrease in MC infiltration in the tumor,
lungs, and bones of mice treated with anti-cKit receptor
antibody (Figures 10A through C and 11A through C).
Representative tryptase and toluidine staining of tumor,
lung, and bone tissue sections is shown in Figures 10D
through F and 11D through F, respectively. Interestingly,
mice treated with anti-SCF also showed significant
decrease in MC accumulation in the tumor, lung, and
bone (Figure 10D(ii), E(ii), F(ii), and 11D(ii), E(ii), and
11F(ii), respectively), confirming the role of SCF in MC
proliferation [10]. Taken together, these findings con-
firm that the decrease in metastasis in the treated
groups (Figure 8) was driven by low MC accumulation.
Discussion
From our previous [8,9] and present study (Figure 1), we
confirmed that BC-associated metastasis is significantly
augmented in mice with arthritis. Previously, we identi-
fied IL-17, IL-6, COX-2, VEGF, MMP-9, and TNF-a as
the major underlying factors responsible for the
increased metastasis in arthritic mice [8,9]. These cyto-
kines play an important role in cancer development and
progression [36-47] and are known to be produced by
MCs [10]. Therefore, we analyzed whether MC accumu-
lation and signaling plays a role in augmented BC-asso-
ciated metastasis.
Data from this study suggests two things:
1. MC population is significantly increased in the bone
and lung of arthritic mice before tumor development
(Figures 3 through 5). This probably acts as a chemoat-
tractant for breast tumor cells, and once the tumor cells
infiltrate the bone and lung microenvironment, they
further augment the accumulation of MCs (Figures 3
through 5); and
2. MCs infiltrate the primary tumor site, accumulate
there (Figure 2A, B), and possibly increase the meta-
static potential of the tumor cells. In the nonarthritic
mice, this accumulation of mast cells in the primary
tumor as well as in the metastatic niches (bone and
lung) is significantly lower than in their arthritic coun-
terparts (Figures 2 through 5), and these mice have sig-
nificantly fewer metastases (Figure 1). We therefore
believe that, in our mouse models, the major driver for
the enhanced metastasis is the MCs.
MCs express the receptor, c-Kit, and interact with its
ligand SCF expressed on tumor cells. We report that
this interaction between MCs and tumor cells is an
underlying mechanism for facilitating metastasis in the
arthritic mice. Because MCs express the c-Kit receptor,
they increase SCF/c-Kit signaling. This sets up a “vicious
cycle” whereby SCF/c-Kit signaling further stimulates
the production of more MCs, which promotes metasta-
sis. We determined that the BM progenitor cells des-
tined to differentiate into MCs is also significantly
increased in the arthritic mice with BC (Figure 7A
through G). We established that the BC cells (expressing
SCF) migrate toward the MCs expressing c-Kit. This
migration was significantly enhanced when MCs were
derived from tumor-bearing arthritic mice (Figure 7H, I).
Importantly, BC cell migration was significantly
decreased when either c-Kit or SCF was blocked by neu-
tralizing antibody (Figure 7H, I).
The in vitro data were validated in vivo in mice treated
with the c-Kit or SCF neutralizing antibodies (Figure 8).
We first determined whether metastasis was attenuated
by blocking the SCF/cKit interaction. Mice treated with
these antibodies had significantly fewer metastases
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Figure 9 Decreased differentiation of mast cells (MCs) from bone marrow (BM) precursors in mice treated with anti-SCF or anti- c-Kit
antibody. (A) Significant reduction in the differentiation of BMMCs in mice treated with neutralizing stem-cell factor (SCF) or cKit antibodies (*P
< 0.05; **P < 0.01). (B through D) Representative images of BMMCs showing diminution of MC population in treated group (A through D, 10
mice). (E) Significant reduction in migration of 4T1 cells toward MCs from mice treated with anti-SCF or anti-cKit (**P < 0.01; ***P < 0.001).
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Figure 10 Significant reduction in number of mast cells (MCs) (tryptase staining) in the tumor, lungs, and bones of mice treated with
anti-SCF or anti-ckit antibody. (A through C) Significant reduction in number of MCs in (A) tumors (**P < 0.01; ***P < 0.001), (B) lungs (*P <
0.05; **P < 0.01), and (C) bones (*P < 0.05; **P < 0.01) of treated mice. (D through F) Representative images of MCs tryptase in (D) tumors
(400×), (E) lungs (600×), and (F) bones (400× magnification) (six mice per experimental group and 10 fields per section per organ). Brown
staining represents MCs tryptase expression.
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(Figure 8). Second, these mice generated fewer BMMCs
(Figure 9A through D), Third, the migration of BC cells
toward these MCs (from treated mice) was significantly
reduced (Figure 9E). These data confirm that SCF/cKit
axis plays a major role in migration of BC cells toward
the MCs in the metastatic niches in the arthritic
condition.
We recognize that c-Kit is expressed in HSCs, MCs,
melanocytes, and germ cells. It is also expressed in hema-
topoietic progenitor cells including erythroblasts, myelo-
blasts, and megakaryocytes. However, with the exception
of MCs, expression decreases as these hematopoietic cells
mature, and c-Kit is not present when these cells are fully
differentiated. Simultaneously, MCs have a role in the
pathogenesis of RA, and inhibition of c-Kit is reported to
inhibit MC activity and also abrogate the contribution of
MCs to synovial inflammation in RA [48]. Recently, it was
also reported that inhibition of the kit ligand/cKit axis
attenuates metastasis in the mouse model, mimicking BC
relapse after radiotherapy [49].
It is of note that the effect on the primary tumor was
less dramatic, and anti-SCF treatment had no effect on
the primary tumor. Along similar lines, anti-SCF treat-

































































































































































Figure 11 Significant reduction in number of mast cells (MCs) (toluidine staining) in the tumors, lungs, and bones of mice treated
with anti-stem cell factor (SCF) or anti- c-Kit antibody. (A through C) Significant reduction in number of MCs in (A) tumors (**P < 0.01), (B)
lungs (*P < 0.05; ***P < 0.01), and (C) bones (**P < 0.01; ***P < 0.001) of treated mice. (D through F) Representative images of MCs toluidine in
(D) tumors, (E) lungs, and (F) bones (200× magnification) (six mice per experimental group and 10 fields per section per organ). Purple-blue
staining represents MCs toluidine expression.
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reducing metastasis. The reason is unknown, and future
studies with other combinations will be needed. Similar
data were also generated in the PyV MT model (data
not shown). These data become relevant, as ckit-SCF
interaction is a major agonist for human MC develop-
ment. It affects proliferation of MC precursors, activa-
tion, chemotactic properties, and MC adhesion, and
changes MC releasability [50,51]. Therefore, this treat-
ment may have the potential to be developed for treat-
ment of human disease. It is important to note that,
even in the nonarthritic BC models (Balb/C with 4T1
tumors and nonarthritic PyV MT tumors), this axis
plays a major role (Figure 7H, I).
Our study shows that in our mouse models, MCs seem
to be an important regulator, inducing metastasis via the
SCF/cKit axis. Therefore we propose that AA creates a
proinflammatory microenvironment within the BM and
increases the numbers of MC precursors that differentiate
into activated MCs expressing the c-Kit receptor. Activated
MCs are recruited to the bone and lung, where they accu-
mulate and attract the tumor cells toward those organs.
Concurrently, mast cells also accumulate in the tumor
microenvironment. This enables the malignant SCF-
expressing BC cells to become more metastatic and cir-
culate in the blood. The circulating BC cells are
attracted to leave the circulation when they encounter
the ckit receptor on MCs in the bone and lungs. SCF
from the tumor cells further triggers the cKit signaling
pathway and signals the differentiation, maturation, and
survival of MCs, remodeling the microenvironment by
intensifying inflammation and releasing the proinflam-
matory cytokines involved in metastasis [10].
This study may have significant clinical implications. It
is reported that women with BC and arthritis have lower
survival as compared with women with BC and no
arthritis [7]. It is also reported that patients with RA
have huge infiltration of MCs [52,53], and MCs promote
tumor growth, migration, and invasion [54,55]. We show
that interrupting the SCF/cKit-MC signaling signifi-
cantly reduces BC-associated bone and lung metastases.
Conclusions
Our data provide clear evidence that MCs play a critical
role in remodeling not only the tumor microenviron-
ment but also the metastatic niche to facilitate efficient
metastasis through the SCF/cKit interaction, especially
in mice with BC and arthritis.
Additional material
Additional file 1: The expression of stem cell factor (SCF) on the
4T1 and PyV MT tumors in vivo from arthritic BC mice ± anti-SCF
treatment. (A) Western blotting showing decreased expression of SCF
on the tumors derived from SKG mice with BC and treated with anti-SCF
versus no treatment (three to four tumors). (B) Graphic representation of
the densitometry analysis of SCF expression by using the image J
software (**P < 0.01).
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